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ABSTRACT 
An overview of psychiatry during the last three decades as practised in a general teaching 
hospital is presented. Psychiatry as an academic subject has matured tremendously during this 
period. The empirical treatments of the 1950s and the 1960s which evoke nostalgic memories, 
have been replaced by modern methods of treatment. However, there is a need to exercise 
caution against the blind acceptance of new and sophisticated research findings in biological psy-
chiatry. Inspite of the bright future facing psychiatry, the identity of psychiatry as a medical 
discipline must be preserved at all cost. Psychiatrists should also realise the dangers of gradual 
fractionation and impersonalisation which threatens the speciality, and makes all possible efforts 
to prevent this. 
Key Words .General hospital psychiatry, three decades overview 
Mr. President, dignitaries on the dais, my 
distinguished colleagues, ladies and gentlemen. 
I wish to express my sincere apprecia-
tion for the opportunity and the honour of 
delivering Dr. Murti Rao oration. 
It is a special privilege to deliver this 
oration in our eminent society's Jubilee year. I 
consider myself twice blessed as this is also 
the jubilee year of the department of 
Psychiatry, KEM Hospital, Bombay which is my 
alma mater. 
Prof. Murti Rao was a great clinician. He 
was a biologically oriented psychiatrist. In tune 
with this, I have chosen to speak to you on 
"Psychiatry-Past Present and Future" as I have 
been involved with the subject for more than 
three decades, from 1959 when I joined the 
department as a student until my retirement as 
Professor and Head in 1989. 
I see before me faces which are familiar 
and friendly. Some of you have been my 
students, some of you are my colleagues and 
some of you are my seniors. Many of you have 
helped me, taught me, encouraged me, 
challenged me and given me pleasure in 
countless ways over a number of years. 
I would like to share with you my past 
memories of psychiatry as it was in the good 
old days of yesterday, my impressions of 
psychiatry as I see it today, and my hopes and 
fears about psychiatry as it could be in the times 
to come. 
BACKGROUND 
In 1959, I qualified MD in general 
medicine. I was interested in the neurosciences. 
I was very impressed by neurologists who could 
localise a lesion to half a centimetre of brain 
tissue in patients who had massive neurologi-
cal disabilities. 
But the neurologists therapeutic skill was 
not equal to his diagnostic skill. Except for 
prescribing physiotherapy or an indwelling 
catheter, there wasn't much that could be done 
for most patients. So I spent some time as a 
visitor in psychiatry. 
The psychiatry department was about 10 
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years old. I had heard a lot of stories about 
psychiatry. Its image was not as presentable as 
it is today. The subject was taught superficially 
or not at all. At conferences, the participating 
doctors seemed as confused as the patients 
they were discussing. I entered the department 
with a lot of uncertainty. 
Everything that I observed in the 
department seemed new and interesting and 
very different from general medicine. I saw 
nurse going around distributing sweets to some 
patients. I believed it was somebody's birthday 
until I was told that it was part of insulin 
treatment and an everyday affair. This was quite 
puzzling. Like all fresh M.D.s I believed that I 
knew all there was to know in medicine. I could 
not recollect anything about carbohydrate 
metabolism and psychiatric treatment. I even 
referred to my text book "Price's Practice of 
Medicine." I don't think the book is in print any 
longer. 
Then I saw a patient who was being 
resuscitated. I asked the attending doctor about 
the nature of the emergency. The doctor 
informed me that this was carbon dioxide 
therapy and not an emergency. Once again I 
referred to my text book. Carbon-dioxide was 
mentioned in the chapter on toxins, poisons and 
antidotes. But there was no mention of carbon 
dioxide in the chapter on therapeutics. 
Next I saw a patient lying down. Some 
people were holding him while the anaesthetist 
was administering anaesthesia. I a*sked 
someone why the.patient had to be restrained 
when he was being anaesthetized for surgery. I 
was told that this was not surgery but 
electroconvulsive therapy. 
I knew nothing about psychiatry. I had 
skipped attending lectures and I kept on 
reading the wrong books. No wonder I found 
psychiatry different and exciting, and I decided 
to continue in psychiatry. 
I told my father who was a family 
physician, about my decision. He was very 
upset. He told me that he had consulted the 
city's best psychiatrists for his patient's 
problems. He could see no difference between 
psychiatric patients and psychiatric doctors. He 
advised me to forget this silly idea and to 
practice medicine like a proper doctor. 
My father had passed the MBBS 
examination in 1929. Psychiatry was not taught 
in those days. Both of us knew nothing about 
psychiatry, but for different reasons. It is not 
surprising that my father did not think much of 
psychiatry, as at that time there were no effec-
tive treatments like electroconvulsive therapy 
or drug therapy; and the physician and the sur-
geon both looked down upon psychiatry with 
disdain and considered it a lot of mumbo jumbo. 
PSYCHIATRY IN THE PAST 
It is difficult to divorce psychiatry's past 
from its present, as the dividing line between 
the two is imperceptible. 
History tells us that the first psychiatric 
unit in a general teaching hospital was 
established in 1924 at the Henry Ford Hospital 
in Detroit, USA (Lebensohn, 1965). The first 
psychiatric unit in a general teaching hospital 
in India was established in 1933 at the R.G.Kar 
Medical College and Hospital in Calcutta 
(Chakarborty, 1970). The Department of 
Psychiatry at the KEM Hospital, Bombay started 
functioning in 1947, twenty two years after the 
hospital was founded (Vahia et al., 1974). 
The early records show that in 1950 there 
were 746 outdoor and 7 indoor patients. In 1995 
there were 7575 out patients, and 1371 
inpatients (Table 1). During these five decades, 
the total hospital attendance (and the 
TABLE 1 
ANNUAL AVERAGE ATTENDANCE 
1947 1950 1971 1995 
Psychiatry 
Dept. of Med. 
Total Hosp. 
-
41,488 
1,22,262 
746 
51,006 
1,57,690 
7,261 
63,340 
3.78,615 
7,575 
101.219 
4,05,424 
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attendance in the Department of General 
Medicine) increased by two or three times. At-
tendance in psychiatry however had increased 
by many more times. Inspite of these impres-
sive figures, psychiarty continued to be the 
Cinderella of medicine. 
Attempts at approaching the hospital 
administration for more facilities and more 
space usually met with the standard 
answefSorry! this is a general hospital and not 
a lunatic asylum." 
In 1954, about twenty years after its 
discovery, 71 patients were treated with elec-
troconvulsive therapy (Abrams, 1994). A total 
number of 1447 treatments were administered 
during the period 1950-1959, since then the 
annual average number of ECTs increased to 
reach maximum of 8629 during the 1970s, de-
creasing to less than that number during the 
1980s and thereafter (Table 2). 
Almost all ECTs were administered 
straight in the 1950s and the 1960s. Almost all 
ECTs administered during the 1970s and the 
1980s were modified with muscle relaxants and 
pentothal (Table 2). 
TABLE 2 
ANNUAL AVERAGE NUMBER OF ECT TREATMENTS 
ECT 
(ST) 
(MODI) 
1950-59 
1,447 
814 
48 
1960-69 
6,589 
5,577 
571 
1970-79 
8,629 
-
ALL 
1980-89 
3,595 
-
ALL 
I am not sure whether this change is for 
the better or for the worse. There is evidence 
that musculoskeletal complications occur in less 
than 1% of unmodified ECT treatment and are 
of little clinical significance (Tharyan et al., 
1993). Complications of greater clinical 
mortality and morbidity such as cardiac arrest 
are significantly more with modified ECT, which 
also increases the likelihood of aspiration, ar-
rhythmias, bronchospasm and apnoea (Tharyan 
et al., 1993; Abrams, 1994; Hash, 1976; Shukla, 
1981). 
Psychotropic drggs were introduced in the 
1950's (Frankenburg, 1994). They revolution-
ized the management of psychiatric illnesses. 
ECT which had been the mainstay in the treat-
ment of psyhosis up to this time now became 
disreputable. In some countries there was 
debate about legislature to ban its use. 
In our country, most patients cannot be 
treated as quickly and as economically with 
drugs as compared to ECT. It is likely that ECT 
will continue to remain on the scene in India for 
many more years. 
When chlorpromazine did become 
easily available, and was prescribed liberally, 
we received frequent emergency calls. Some 
patients who had been prescribed 
chlorpromazine, had developed spasms or 
dystonia. The doctor who was not familiar with 
the drug could not decide whether the patient 
had tetanus or a seizure or a drug reaction. 
When I joined the department in 1959, 
cardiazol was still being used to induce 
convulsions. It was effective in resistant 
hallucinosis not responding to other treatments. 
Its mechanism of action was different from 
electrically induced convulsions. Cardiazol 
convulsions were clonic-tonic rather than 
tonic-clonic like electrically induced 
convulsions. 387 cardiazol treatment were 
administered during the period f956-1959. 
These convulsions were not smooth. They 
varied in intensity ranging from a mild stun to 
severe bone breaking seizures. Titrating the 
dose of the drug was difficult. The patient 
experienced an intense fear during the interval 
between the intravenous injection of the drug 
and the onset of the seizure. There were 
frequent complications like dislocations and 
fractures and the treatment was discontinued 
in 1960 (Alexander, 1966). 
An amusing incident comes to my mind. 
One day I received an urgent telephone sum-
mons from my chief, Dr. K.M. Masani. He was 
the head of the department at the J.J. Hospital 
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where I had worked for some time. Dr. Masani 
had received a message that, as the doctor who 
regularly administered ECTs was absent, he was 
asked to take over the ECT sessions on that 
particular day. Dr. Masani was trained in 
psychoanalysis. When I reached the ward he 
was in a state of panic. He asked me to do the 
needful as he knew nothing about ECT and had 
never used the treatment. "You mean you are 
only familiar with cardiazol, Sir ?" I asked him. 
"I don't know anything about cardiazol either" 
said Dr. Massani. "My patients receive a 
different kind of shock after my treatment is 
over, when I send them my bill for professional 
services" said Dr. Masani. 
Another time, two patients had been 
prepared for treatment. One was to be treated 
with cardiazol while the other was to be 
interviewed using intravenous pentothal. I 
decided to do the cardiazol first and the 
pentothal afterwards and instructed the nurse 
accordingly. She handed over a filled syringe 
to me. I injected the drug fairly rapidly into the 
first patients's vein as cardiazol is supposed to 
be injected, and waited for the convulsions. I 
was horrified when the patient yawned, closed 
his eyes, became limp and stopped breathing. 
The syringes must have got mixed up. I had 
injected pentothal instead of cardiazol. Luckily, 
both the patient and the treating physician could 
be resuscitated, and recovery was uneventful. 
In the 35 years that I have been 
practising psychiatry, nothing matches the 
successful development of psychopharmaco-
logical therapies, and nothing is as 
disappointing as the dismal attempts to 
advance psychoanalysis as a treatment 
procedure, barring a few exceptions. In 
practice, psychoanalysis is the most time 
consuming and expensive of all therapies. But 
it is reserved for those who are minimally ill or 
who are not ill at all. This is a remarkable 
phenomenon in medicine where the most 
complex treatment is reserved for the least 
severely affected patient (Shepherd, 1982). 
I remember a patient who was assigned 
for analytical psychotherapy to a new house 
psysician in the department. The therapy was 
continued regularly five days in a week for the 
first year. The house physician was then 
promoted to registrar. The therapy continued 
regularly for the next year. The registrar was 
then promoted to the professional staff. The 
therapy continued as regularly as before. By 
this time the therapist was heavily into analysis 
and he went abroad for further studies. But the 
therapy continued, either by correspondence or 
by telephone. Eventually the therapist returned 
to Bombay. In the meantime the patient had 
expired. However the therapist insisted that 
therapy must still continue with the patient's wife 
or with his son-why, because the patient had 
died before the analysis was complete. 
There is a popular belief that certain 
treatments like analysis, meditation or herbal 
medicine are safe alternatives, as they have 
no adverse effects like allopathic medicines. 
Nothing oan be further from the truth. There 
are many recent reports about repressed 
memory therapy harming patients and devas-
tating families (McElroy, 1995; Frankel, 1995; 
Jaroff, 1993). More than seven thousand 
individuals and families have sought assistance 
from the False Memory Syndrome 
Foundation in Philadelphia since its inception 
in 1992. 
Shapiro has reported that 62.96% of 27 
patients on long term meditation therapy 
suffered from adverse effects (Shapiro, 1992). 
These were disorientation, decreased 
attentional clarity, increase in awareness of 
negative qualities of others, increased 
discomfort with family and friends and 
alienation. 
Herbal indigenous products are used by 
a large proportion of the population. They are 
advertised in the lay press and are freely 
available everywhere. They are not regulated 
by governmental food and drug agencies. Their 
safety and efficacy have not been proved. Most 
contain multiple ingredients. Many contain 
alkaloids and aflatoxins. They can cause a wide 
variety of hepatotoxicity ranging from mild hepa-
titis to hepatocytotoxic necrosis, cholestasis, 
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chronic hepatitis and cirrhosis (Koff, 1995). 
Sternbach synthesized chlordiazepoxide 
in the 1950s and the drug became valuable in 
1960 (Kaplan, 1993). Our hospital did not 
dispense anxiolytics free of cost. So carbon 
dioxide inhalation therapy was used for 
cathartic relief in anxious patients, who were 
verbally unable to express confictual, guilty and 
devious thoughts. This rather crude and 
cumbersome method of producing catharsis 
was gradually replaced in 1980 by modern and 
sophisticated chemical and verbal abreactive 
methods. 
The insulin treatment which was 
practiced in our department was not the classi-
cal coma therapy as described by Sakel in 1937 
(Sakel, 1937). Patients who were anxious and 
depressed and who had lost appetite and weight, 
were prescribed insulin in hypoglycemic 
sub-coma doses. They felt better and soon 
regained their weight. 
The treatment was discontinued in 1980 
as the same results could be achieved with 
anxiolytic and antidepressant drugs. 
TABLE 3 
ANNUAL AVERAGE NUMBER OF CO, TREATMENTS 
co2 
1950-59 
1,608 
1960-69 
6,204 
1970-79 
1,501 
1980-89 
148 
TABLE 4 
ANNUAL AVERAGE NUMBER OF INSULIN 
TREATMENTS 
1950-59 
1241 
1960-69 
4524 
1970-79 
1988 
1980-89 
798 
The history of medicine is largely the 
history of the placebo (Shapiro 1968). Quite of-
ten a placebo effect is the single action which 
all drugs have in common. In some instances it 
is also the only useful action which medications 
exert (Modell, 1968). 
The story goes that Dr. Rebello, the first 
appointed chief of dermatology at the KEM 
Hospital had observed that a large number of 
patients with skin problems were highly strung 
and did not need medication. He used to preach 
"Shanti" and advise them to try and relax. Once, 
a disgruntled patient complained that he had 
come to the hospital for treatment for his skin 
disease and not to listen to his "Lambi chori 
batt". He insisted that he must have some medi-
cation. Thereafter Dr. Rebello routinely 
prescribed an injection of normal saline or 
distilled water to these patients with excellent 
results. To avoid further confrontations he 
labelled this as "Injection 'R* Solution" ('R' for 
Rebello). 
The psychiatry department adopted this 
treatment for some of its patients with 
equally gratifying results. Patients would come 
for these injections regularly every week from 
distant suburbs many kilometers away from 
Bombay. 
The power of the placebo cannot be 
underestimated. Placebo effectiveness is 
variously reported in the literature ranging up 
to 69% and averaging out at 35.2% (Beecher, 
1955; Dhume, etal., 1975; Diehi, 1933; Gorden, 
1970; Green, 1964; Pogge, 1963; Shapiro, 
1968; Wolf & Plinsky, 1954). At the same time 
placebos also have been reported to produce 
side effects which affect almost every organ 
system in the body (Meyer & Herxheimer. 1972; 
Meyer, 1968; Gorden. 1970; Shapiro, 1968; 
Beecher, 1962; Fisher, 1965; Honigfeldt, 1964). 
Addiction, habituation and even anaphylaxis 
have all been reported (Lealie, 1954; Vicar, 
1969) (the lethal dose of placebo is not known). 
The consumer protection courts should have a 
field day trying to pass judgement on litigations 
involving the use of a placebo. It had been 
reported just recently that placebos and 
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acupuncture both act by releasing endorphins 
in the brain periaqueductal areas and the 
raphae (Tyrer, 1992; Levine et al., 1978; Levine 
1979). 
Psychiatry is an imperfect science. 
Unlike general medicine where you can 
diagnose pneumonia, isolate pneumococci and 
prescribe penicillin, the exact cause of a psy-
chiatric illness, and the mode of action of a par-
ticular treatment may not be precisely known 
at a point in time. Quite often, what is well known 
today was not known at all yesterday, and will 
be obsolete by tomorrow. 
This was psychiatry as I saw it in the 
1960s. 
PSYCHIATRY IN TRANSITION 
BY this time I had seen a lot of psychia-
try and I decided to see what psychiatry was 
like in other parts of the world. 
I spent some years in the United States. 
When I returned to India in 1970, I noticed a 
great deal of change. Psychological medicine 
had come of age. It had gradually evolved into 
a modern and sophisticated neurosciences. I 
don't know about psychiatrists, but psychiatry 
had certainly become more respectable. It had 
gained in prestige what it had lost in terms of 
providing entertainment. Carbon dioxide 
therapy, insulin therapy and analytical therapy 
were amusing incidents from the past. 
Psychiatry had also become too 
important subject to be left to psychiatrists. Now 
it was public property. It was the province of 
people who were in no way connected with it 
either as patients or as its practitioners. Unlike 
cardiology or neurology, every other person had 
his or her own views about psychiatry and did 
not hesitate to express them. The subject was 
talked about, discussed and criticised by 
people who were least qualified to do it. 
Amateur psychology magazines, health guides 
and self help books had almost as large a 
circulation as Playboy and Penthouse 
magazines. 
Psychiatrists too were moving away from 
psychological medicine into territories which 
were already occupied by non-medical and 
paramedical professionals (Ghiselli, 1963; 
Reese, 1972; Levinson, 1977; Greenblatt, 1977; 
1978;Schenke, 1986). 
Some psychiatrists had become 
management Gurus. All of us spend some time 
in administrative and management duties. We 
have learnt to do this by common sense and by 
experience. None of us has a MBA 
degree. As a matter of fact the psychiatrist is 
ill-suited for management either by training or 
by temperament. His approach to a problem is 
through reflection and interpretation, while in 
fact what may be required is quick action and 
clear direction (Silver, 1989). This kind of switch-
ing of sides or loyalties may be all right for poli-
ticians at the time of national elections. But it is 
not all right for professionals, especially when 
the election are already over. 
When I joined the department in 1959 
very few post graduate students chose to spe-
cialize in the neurosciences. Now the situation 
is very different. Top ranking students compete 
for psychiatry residency post. Most of them pas 
the DPM, MD and DNB examinations with 
credit. Their competence and training is 
acknowledged at various teaching institutions 
in India and all over the world. 
In 1947 the department had one visiting 
lecturer in psychiatry and one house physician. 
Today there are. six psychiatrists on the 
professional staff and twenty two residents, 
apart from clinical psychologists, social 
workers and occupational therapists. 
The academic image of psychiatry had 
also improved. Staff members presented 
papers at local, national and international 
conferences. Some members were actively 
involved with local and national scientific 
bodies. They held important positions as office 
bearers (Appendix 1). Many collaborative 
studies were planned and executed (Appendix 
2). A large number ot prestigious papers were 
published. Some of them are landmarks and 
are quoted in standard text books and 
monographs. (Appendix 3). All this was largely 
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due to the efforts of my distinguished teachers 
and predecessors Dr. Vahia and Dr. Bagadia. 
Staff members also received many distinctions, 
awards and prizes (Appendix 4). I myself re-
ceived many surprises and very few prizes. 
THE SACRED COWS OF PSYCHIATRY 
I am aware of the rich variety of recent 
research findings in biological psychiarty. 
However, I am not very clear about their 
significance. 
To recapitulate: 
DOPAMINE SCHIZOPHRENIA AND 
ANTIPSYCHOTICS 
The dopamine hypothesis states that 
schizophrenia is a hyperdopaminergicdisease. 
Dopamine agonists worsen the symp-
toms while dopamine antagonists prove them 
by blocking dopamine D2 receptors (Mathyse, 
1973). There are limitations to this theory. 
1. In schizophrenia there is hypofrontality or hy-
pofunctioning of the prefrontal cortex. This has 
been demonstrated with CBF measurements 
using the PET scan. 
2. The psychotic symptoms associated with 
frontal lobe damage and the cognitive and 
motivational symptoms in Parkinson's disease 
are similar to the negative symptoms of schizo-
phrenia e.g., apathy, avolition, flattened affect, 
etc. They may be due to low dopaminergic 
activity (DA). 
3. In post-stroke patients, the low prefrontal 
cortical activity is associated with an increase 
in sub-cortical DA. 
4. Lesions of DA neurones in the prefrontal 
region result in an increase in homovanillic acid 
(HVA), the DA metabolite in the striatal region. 
5. Varying values of HVA ranging from low, 
normal to high have been reported in 
schizophrenia. 
Therefore it is possible that cortical 
hypodopaminergia may be related to subcorti-
cal hyperdopaminergia (Table 5). 
TABLE 5 
DOPAMINE, SCHIZOPHRENIA AND ANTIPSYCHOTICS 
PET 
Symptoms 
DA 
HVA 
Drugs 
Site 
Cortex 
J, Hypofrontality 
Negative 
Parkinson's Dis. 
Fl. lobe damage 
I 
i± 
Atypical D1.D4 
5HT2, 5HT7 
Mesolimbic 
Striatum 
-
Positive 
T 
t ± 
Typical D2 
Nigrostriatal 
This can explain the concurrent presence 
of negative and positive symptoms and also the 
reported inconsistent HVA values (Davis et a.,I 
1991; Davidson, 1988; Davila, 1988). 
In so far as drugs are concerned, the 
limitations are : 
1. Dopamine agonists do not induce the 
negative symptoms of schizophrenia, but only 
the positive symptoms. 
2. Many schizophrenics are drug resistant. 
3. Antipsychotics effectively treat almost all 
psychotic and agitated patients including 
manics and not only schizophrenics. 
4. Clozapine and other atypical and highly 
effective antipsychotics have affinity forD-| and 
D4 and 5HT2 receptors unlike typical 
neuroleptics which have D2 receptor affinity. 
The overall conclusion is that there may 
be a dysregulation of DA transmission in 
schizophrenia rather than a hyper or hypo-
dopaminergic state. 
Both typical and atypical antipsychotics 
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exert a modulatory action by blocking DA 
receptors in different brain DA subsystems like 
the mesaocortical or the nigrostriatal system, 
(Lader, 1983; Civelli, 1993; Carlosson, 1990; 
Meltzer, 1996). 
MONOAOMINES, AFFECTIVE DISORDERS 
AND ANTIDEPRESSANTS 
The catecholamine, indoleamine and 
dopamine hypotheses of depression state that 
some depressions may be associated with ab-
solute or relative deficiency of norepinephrine 
(NE), 5-hydroxytryptamine (5HT) or dopamine 
(DA) respectively (Randrup et al., 1975; Lapni 
& Oxenking, 1989; Bunney & Davis, 1965; 
Schildkrant1965). 
Drugs which increase or potentiate these 
brain transmitters may have antidepressant 
properties. 
Tricyclic antidepressants (TCAs) or 
monoamine reuptake inhibitors (MARIS) 
increase synaptic NE by inhibiting its reuptake. 
The selective serotonin reuptake 
inhibitors (SSRIs) increase synaptic 5HT by 
inhibiting its reuptake. 
The implication that some depressions 
may respond to TCAs while some may respond 
to SSRIs is naive. There is data suggesting an 
earlier onset of antidepressant action with 
combined 5HT and NE reuptake blockade 
(Nelson et al., 1991). Further-more 
Venlafaxine, a potent new antidepressant is an 
SNRI. It inhibits the reuptake of both 5HT and 
NE (Feigner, 1994). 
Tianeptine, a novel TCA, is an SSRE 
instead of an SSRI. It enhances the synaptic 
5HT reuptake instead of inhibiting it, its action 
is therefore opposite to the action of SSRIs. 
(Wilde, 1995; Ayd, 1994). 
Tianeptine also blocks the heightened 
HPA axis response to stress and prevents 
structural changes in the brain induced by 
corticosteroids (Wilde, 1995; Ayd, 1994). 
Amoxapine is marketed as an antidepres-
sant. It increases synaptic NE like a TCA and it 
has a DA blocking action like an antipsychotic 
(Ayd, 1994). 
Amineptine, another TCA increases the 
release and reduces the reuptake of DA (Ayd, 
1994). 
Risperidone, atypical antipsychotic with 
both D2 and 5HT2 receptor blocking properties 
has been used successfully in treating major 
depression and schizoaffective depression 
(Ayd, 1994). 
Finally, clozapine a potent atypical 
antipsychotic which had both D-|, D4 and 5HT2 
to 5HT7 receptor blocking properties has been 
used to treat schizoaffective and psychotic 
mood disorders (Darsa, 1993; Baun, 1994; 
McElory, 1991; Ayd, 1994) 
I believe that by this time most of you 
must be as thoroughly confused as I am. The 
treatment of depression involves drugs with a 
variety of mechanisms of action viz., those 
which increase 5HT, DA and NE, those which 
decrease 5HT and DA, those which block both 
D2 and 5HT2 receptors, those which block both 
D1 and D4 and 5 HT2 to 5HT7 receptors. And 
those which attenuate the stress response of 
the HPA axis (Table 6). 
TABLE 6 
MONOAMINES, AFFECTIVE DISORDERS AND 
ANTIDEPRESSANTS 
TCA/MAO 
SSRI 
SNRI 
SSRE 
AMINEPTINE 
AMOXAPINE 
DA 
i D2 
D1 D4 
i 
NE 
T 
T 
T 
5HT 
T 
t 
i 
1 SHT, 
HPA 
4 
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How can this be possible? Can drugs 
having diverse and even diametrically opposite 
modes of action produce the same end result? 
One speculative answer to this question 
is "YES." It is possible because the isodendritic 
core of the brain stem which has extensive pro-
jections to various brain areas, comprises of 
dopaminergic, cholinergic, serotoninergic and 
noradrenergic neurons. Each neuronal system 
may be modulating the action of some other 
neuronal system rather than acting in isolation 
(Jesteetal., 1988). 
The second answer to this question, 
which is probably more correct is "GOK" or "God 
Only Knows"; or better still "EGDNK" which 
means "Even God Does Not Know." 
THE ANATOMY OF THE MIND 
As if all this is not confusing enough, a 
number of neurobiologicai and neuroimaging 
studies have added fuel to the fire. 
A neuroanatomical basis for panic 
disorders at the brain stem, limbic and 
prefrontal cortex areas is reported (Gorman et 
al., 1989). 
Obsessive compulsive disorder has been 
associated with lesions of the caudate nucleus 
and orbitofrontal gyrus (George et al., 1992). 
Anxiety is accompanied by arousal 
changes in reticular formation and frontal lobe, 
and increased CBF or hyperfrontality (Mathew 
and Wilson, 1990). 
The dexamethasone suppression test 
which is reported abnormal in depression is also 
reported to be abnormal in hysteria (Tunea et 
al., 1996). 
Schizophrenia is a brain disease with 
abnormal hemispheric asymmetry, increased 
lateral ventricular size, abnormalities in the left 
temporal lobe, and limbic structures, hypofron-
tality and changes in cerebellar vermis and 
festigial nucleus (Chua & McKenna, 1995; 
Shenton et al., 1992, Martin & Mathias, 1995, 
Mesulam, 1990). 
Neuroanatomical observations in patients 
who develop an affective disorder after 
cerebrovascular disease have shown 
involvement of both cerebral hemispheres, and 
all four hemispheric poles viz.right anterior, right 
posterior, left anterior and left posterior, 
depending upon whether the-affective disorder 
is manic or depressive, and whether the 
depression is primary or secondary, unipolar or 
bipolar (Starkstein, 1989; Bolla-Wilson et al., 
1989; Jesteetal., 1988). 
The structural changes reported in both 
schizophrenia and affective disorder show no 
significant differences between the two groups 
(Jeste et al., 1988). Neither are there 
significant differences in the CT scan indices 
or CBF values between the two groups. 
Several reasons have been cited for these 
findings (Jesteetal., 1988). 
Frontal lobe dysfunction has been 
involved in many psychiatric disorders (David, 
1992) e.g., personality disorders, obsessive 
compulsive disorder, schizophrenia, depression, 
catatonia, conduct disorders, manic thought 
disorders, anorexia, hysteria and delusional 
disorders (Gorenstein, 1982; Beharetal., 1984; 
Parfiit, 1956; Reading, 1991; Robinson, et al., 
1980; Matters, 1991; McGrath, 1991; Benson, 
andstuss, 1991). 
Even the concept of empathy or 
emotional interpersonal communication, a term 
which is so difficult to define, is hypothesised 
to have a neurological basis involving the right 
hemisphere, amygdala, hypothalamus, and the 
brain stem (Brothers, 1989). 
This list probably includes most of the 
brain structures mentioned in Gray's anatomy. 
So far the cauda equina seems to have 
escaped. 
What does all this mean? What is its 
significance? 
I have reached an age when I am too old 
to be called young and too young to be called 
old, so I can afford to read the bottom line. And 
the bottom line is that we should know the 
differences between medical facts and 
medical myths. All new, speculative and 
sophisticated findings should be interpreted with 
caution. We must know what we do know and 
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what we do not know very clearly, with regard 
to new discoveries. 
If this is not kept in mind, then in the 
future all of psychiatry will be medical, none of 
it will be psychological. And as Professor 
Eysenck had predicted physicians and neurolo-
gists will treat the psychotics, psychologists and 
social workers will treat the neurotics, and 
psychiatrists like dinosaurs will soon cease to 
exist. 
THE FUTURE OF PSYCHIATRY 
What about the future of psychiatry? The 
future of psychiatry is as controversial as its 
past. 
On the one hand, psychiatry has a bright 
future. No one in the early forties could have 
predicted that in few years we would see the 
appearance of a variety of drugs which have 
almost emptied the beds in mental hospitals all 
over the world. Today the psychiatrist can pick 
and choose a drug from a mountain of medica-
tions which can modify almost every aspect of 
human behaviour. There are stimulants, 
sedatives, uppers, downers, drugs to make you 
sleep, drugs to keep you awake, drugs to turn 
you on and to turn you off, tranquillisers, 
antidepressants, mood stabilizers, mind 
expanders, memory enhancers and what have 
you. 
Future discoveries and innovations 
whose nature we cannot even imagine will bring 
about still greater progress. Newer medicines, 
manipulations and measurements will increase 
our knowledge and add sophistication to our 
therapies. 
On the other hand, the future of 
psychiatry faces two real dangers. 
The first is the danger of the 
fractionation or decimation of psychiatry. 
On the somatic side, psychiatry has 
already lost a large proportion of its patient 
population to other disciplines like neurology 
and internal medicine. Patients with dementia 
are now referred to neurologists for diagnosis, 
investigations and treatment. 
But all are agreed about the need to 
preserve psychiatry's connection to medicine. 
This integration of psychiatry within the main-
stream of medicine requires that the physician 
must be a psychiatrist and the psychiatrist must 
also be a physician. 
On the psychic side, psychiatry is 
surrounded by practitioners of alternative 
methods of medicine. An encyclopedia of 
alternative medical practice lists more than 30 
such methods of healing (Olsen, 1989). We 
have lay counsellors, hypnotists, psychic 
healers, astrologers, soothsayers, poojaris who 
use pagers, God men who may not be good 
men, sadhus and saints. We even have what is 
called sexologists. Some time back, sex was a 
pleasant pastime which involved a little bit of 
pushing and a little bit of pulling in the right 
places. Sexologists have changed all that. And 
today, you have to know the physiology and the 
biochemistry of human reproduction before you 
can experience an orgasm. 
If psychiatry is to survive, then it is 
important that we psychiatrists create such a 
climate, that all these people who seek alterna-
tives to psychiatry to be able to cope with their 
problems will want to seek help from us instead. 
The second danger facing psychiatry is 
the danger of impersonalisation of medicine. 
At all times the doctor is the person on whom 
the patient and his family rely in times of 
physical or psychological distress. They know 
that he is there and is willing to listen with 
sympathy. Quite often this is the only treatment 
which is required. This traditional relationship 
between the doctor and the patients is unique, 
and medicine is no longer medicine if this 
relationship disintegrates. 
Today conventional medicine is being 
replaced by computerized medicine. The 
doctor tends to be a technician. He is busy 
studying esoteric investigations and punching 
computer keys, while he expects someone else 
to talk, to listen and to relate to the patients. 
In future societies, it is perhaps possible 
that psychiatry may not exist as a medical 
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speciality. But it is impossible that the traditional 
doctor can be replaced by a machine. If 
medicine does become progressively 
impersonalised, then the disintegration of 
psychiatry which is one of the youngest 
branches of medicine, will precede the 
disintegration of medicine. 
If we wish to preserve psychiatry and 
clinical medicine for future generationsjt is 
necessary that we make all possible efforts to 
be personally involved with the patient. 
It is said that a good lecture must be like 
a woman's dress. It must be long enough to 
cover most of the subject, but short enough to 
be interesting. I have followed President 
Roosevelt's advice for my talk today. I have 
been sincere in what I had to say, I have tried 
to be brief, and it is time for me to be seated. 
Ladies and gentlemen, this has been 
memorable day for me. I want you to know that 
it has been a singular honour to have been given 
the opportunity of addressing you today. Once 
again I thank the organizers of this conference 
for arranging this function, and I thank you all 
for gracing the occasion with your presence. 
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